Sam-A Pharm Past Earnings Performance
Past criteria checks 5/6
Sam-A Pharm has been growing earnings at an average annual rate of 30.3%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 9.1% per year. Sam-A Pharm's return on equity is 10.7%, and it has net margins of 22%.
Key information
30.3%
Earnings growth rate
30.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 9.1% |
| Return on equity | 10.7% |
| Net Margin | 22.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Key Things To Consider Before Buying Sam-A Pharm. Co., Ltd (KOSDAQ:009300) For Its Dividend
Apr 08
Is Sam-A Pharm (KOSDAQ:009300) A Risky Investment?
Mar 04How Much Did Sam-A Pharm's(KOSDAQ:009300) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 28
Four Days Left To Buy Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Before The Ex-Dividend Date
Dec 24Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Is Yielding 1.6% - But Is It A Buy?
Dec 07Revenue & Expenses BreakdownBeta
How Sam-A Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 97,211 | 21,374 | 29,592 | 6,398 |
| 30 Sep 23 | 95,931 | 20,338 | 28,825 | 6,431 |
| 30 Jun 23 | 95,324 | 20,387 | 27,952 | 5,441 |
| 31 Mar 23 | 87,159 | 15,531 | 30,899 | 1,451 |
| 31 Dec 22 | 81,700 | 11,912 | 26,661 | 3,771 |
| 30 Sep 22 | 75,479 | 11,029 | 24,036 | 2,977 |
| 30 Jun 22 | 66,172 | 7,520 | 22,587 | 3,258 |
| 31 Mar 22 | 63,638 | 7,000 | 16,024 | 7,600 |
| 31 Dec 21 | 54,666 | 3,392 | 20,814 | 3,829 |
| 30 Sep 21 | 50,907 | 178 | 20,969 | 3,776 |
| 30 Jun 21 | 50,870 | -1,115 | 21,690 | 4,120 |
| 31 Mar 21 | 48,548 | -1,650 | 23,102 | 2,847 |
| 31 Dec 20 | 53,653 | 124 | 22,780 | 3,681 |
| 30 Sep 20 | 59,775 | 3,392 | 22,977 | 4,161 |
| 30 Jun 20 | 64,025 | 5,986 | 25,136 | 4,133 |
| 31 Mar 20 | 70,346 | 9,128 | 25,824 | 4,843 |
| 31 Dec 19 | 71,560 | 10,197 | 26,105 | 5,386 |
| 30 Sep 19 | 70,715 | 9,807 | 27,220 | 5,728 |
| 31 Dec 18 | 66,947 | 8,801 | 26,278 | 4,889 |
| 30 Sep 13 | 54,667 | 7,886 | 22,790 | 4,466 |
| 30 Jun 13 | 54,192 | 8,548 | 22,691 | 4,071 |
Quality Earnings: A009300 has high quality earnings.
Growing Profit Margin: A009300's current net profit margins (22%) are higher than last year (14.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A009300's earnings have grown significantly by 30.3% per year over the past 5 years.
Accelerating Growth: A009300's earnings growth over the past year (79.4%) exceeds its 5-year average (30.3% per year).
Earnings vs Industry: A009300 earnings growth over the past year (79.4%) exceeded the Pharmaceuticals industry 34.6%.
Return on Equity
High ROE: A009300's Return on Equity (10.7%) is considered low.